Viking Therapeutics, Inc. (VKTX)财务
NASDAQ · Healthcare · Biotechnology · 员工53人 · CEO Brian Lian
- 股价
- $27.28 +1.56%
- 市值
- $34.8亿
- 企业价值
- $30.6亿
- 最近财报
- Q3 '26 2026-10-29提交
- 下次财报
- 2027-02-10 EPS预期 -$1.38
营收(TTM)$0– 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)–– 对比去年同期营业利润 -$6.49亿
净利润(TTM)-$6.27亿-164.2% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$4.63亿-106.0% 对比去年同期资本支出 $0
稀释EPS(TTM)-$5.40-154.7% 对比去年同期最近4个季度之和
净现金$7.05亿-1.2% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $34.8亿 EV $30.6亿
- 营收
- $0 过去12个月
- 营收增速
- – FY2026年一致预期
- 净利润率
- – 净利润 / 营收,TTM
- P/E
- -5.1× 预期 -5.1×(FY2026)
- P/S
- 0.0× 股价 / 营收,TTM
- EV / EBITDA
- -4.9× TTM
- 自由现金流
- -$4.63亿 过去12个月
- 净利润
- -$6.27亿 过去12个月
- 营收预期
- $717万 FY2026年一致预期
- 盈利
- 2027-02-10
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-28):营收无,EPS 低于预期46.2%营收–,预期–(–);EPS -$1.55,预期-$1.06(-46.2%)。
- 稀释股数一年内增加5.1%Q3 '26稀释股数1.18亿,一年前为1.12亿。
- 净现金 $7.05亿现金 + 短期投资 $9.6亿,含租赁债务 $2.55亿;一年前净现金 $7.14亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $0 | $0 | – |
| 营业利润 | -$1.87亿 | -$9860万 | -89.8% |
| 净利润 | -$1.83亿 | -$9080万 | -101.8% |
| 稀释EPS | -$1.55 | -$0.81 | -91.4% |
| 经营现金流 | -$1.38亿 | -$9400万 | -47.0% |
| 资本支出 | $0 | $0 | – |
| 自由现金流 | -$1.38亿 | -$9400万 | -47.0% |
| R&D | $1.67亿 | $9000万 | +85.4% |
| 股权激励费用 | $1790万 | $734万 | +143.9% |
实际 vs 一致预期
2026-10-28| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| EPS(一致预期口径) | -$1.55 | -$1.06 | -46.2% |
来自2026-10-28发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$4.63亿
- 资本支出
- $0
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- $2.51亿
- 股权激励费用
- $4790万
- 自由现金流
- -$4.63亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -5.1× | – | – |
| EV / EBITDA | -4.9× | – | – |
| EV / 营收 | 0.0× | – | – |
| 股价 / FCF | -7.5× | – | – |
| 股价 / 净资产 | 5.5× | 4.6× | 1.8× – 6.2× |
| FCF收益率 | -13.3% | -6.7% | -13.4% – -2.0% |
| 投入资本回报率 | -76.9% | -36.6% | -61.5% – -17.1% |
| 净资产收益率 | -117.3% | -33.6% | -56.3% – -12.5% |
分析师
一致目标价 $82.00 (+200.6%)
区间 $34.00 – $120.00 · 评级 Buy
强烈买入1
买入22
持有1
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $717万 | – | -$5.32 | -66.7% | -5.1× | 13 |
| FY2027 | $735万 | +2.5% | -$5.15 | +3.2% | -5.3× | 15 |
| FY2028 | $2.17亿 | +2,854.9% | -$3.93 | +23.6% | -6.9× | 15 |
| FY2029 | $4.83亿 | +122.2% | -$1.69 | +57.0% | -16.1× | 9 |
| FY2030 | $11.5亿 | +138.2% | $1.66 | +198.4% | 16.4× | 6 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Viking Therapeutics, Inc.在近期10-Q / 10-K文件中标记的全部161项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| $8.8万 | $0 | – | – | – | – | |
| Accounts Payable, Current | $8210万 | $441万 | +1,761.2% | $5330万 | $981万 | +442.7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $79.6万 | $203万 | -60.8% | $928万 | $1730万 | -46.2% |
| Additional Paid in Capital, Common Stock | $19.1亿 | $14亿 | +36.0% | $14.9亿 | $13.7亿 | +8.6% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 482万 | -14.9万 | +3,322.7% | 735万 | 745万 | -1.4% |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | -$170万 | $37.4万 | -554.0% | $37.8万 | -$78.8万 | +148.0% |
| APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition | $1790万 | $734万 | +143.9% | $4080万 | $2970万 | +37.4% |
| Assets | $9.77亿 | $7.39亿 | +32.2% | $7.16亿 | $9.08亿 | -21.2% |
| Assets, Current | $9.73亿 | $7.39亿 | +31.7% | $7.16亿 | $9.07亿 | -21.1% |
| Assets, Fair Value Disclosure | $8.36亿 | $6.83亿 | +22.3% | $5.99亿 | $8.95亿 | -33.0% |
| Cash and Cash Equivalents, at Carrying Value | $6.78亿 | $1亿 | +575.1% | $1.66亿 | $2670万 | +521.6% |
| Cash and Cash Equivalents, Fair Value Disclosure | $5.53亿 | $6880万 | +703.7% | $5910万 | $1860万 | +218.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $6.78亿 | $1亿 | +575.3% | $1.66亿 | $2670万 | +521.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $5.52亿 | $6650万 | +729.9% | $1.39亿 | -$2870万 | +585.0% |
| Common Stock, Capital Shares Reserved for Future Issuance | 2360万2025-12-31 | 2470万 | -4.4% | 2360万 | 2470万 | -4.4% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 3亿 | 3亿 | 0.0% | 3亿 | 3亿 | 0.0% |
| Common Stock, Shares, Issued | 1.28亿 | 1.12亿 | +13.4% | 1.15亿 | 1.12亿 | +2.9% |
| Common Stock, Shares, Outstanding | 1.28亿 | 1.12亿 | +13.4% | 1.15亿 | 1.12亿 | +2.9% |
| Common Stock, Value, Issued | $1000 | $1000 | 0.0% | $1000 | $1000 | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$1.84亿 | -$9020万 | -103.6% | -$3.58亿 | -$1.1亿 | -224.8% |
| Convertible Notes Payable, Noncurrent | $2.51亿 | – | – | $215万2015-12-31 | $126万 | +70.2% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Federal, State and Local, Tax Expense (Benefit) | – | – | – | $1000 | $1000 | 0.0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $1000 | $1000 | 0.0% |
| Debt Securities, Available-for-sale | $2.82亿 | $6.14亿 | -54.1% | $5.4亿 | $8.76亿 | -38.4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $1000 | $101万 | -99.9% | $93.2万 | $80.2万 | +16.2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $122万 | $14.4万 | +750.0% | $8.8万 | $108万 | -91.8% |
| Debt Securities, Available-for-sale, Amortized Cost | $2.83亿 | $6.13亿 | -53.8% | $5.39亿 | $8.76亿 | -38.5% |
| Debt Securities, Available-for-sale, Current | $2.82亿 | $6.14亿 | -54.1% | $5.4亿 | $8.76亿 | -38.4% |
| Debt Securities, Available-for-sale, Gain (Loss) | $02026-03-31 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | – | – | – | $1万 | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | 113 Security | 82 Security | +37.8% | 59 Security | 132 Security | -55.3% |
| Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance | – | – | – | 100万2014-02-28 | – | – |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$6040万 | -$3320万 | -81.9% |
| Deferred Federal, State and Local, Tax Expense (Benefit) | – | – | – | -$1.01亿 | -$4510万 | -123.2% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$1960万 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$2080万 | -$1190万 | -74.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $1.34亿2025-12-31 | $9310万 | +44.1% | $1.34亿 | $9310万 | +44.1% |
| Deferred Tax Assets, Gross | $2.65亿2025-12-31 | $1.64亿 | +61.2% | $2.65亿 | $1.64亿 | +61.2% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Net of Valuation Allowance | $24.7万2025-12-31 | $28.1万 | -12.1% | $24.7万 | $28.1万 | -12.1% |
| Deferred Tax Assets, Operating Loss Carryforwards | $6820万2025-12-31 | $4080万 | +67.1% | $6820万 | $4080万 | +67.1% |
| Deferred Tax Assets, Operating Loss Carryforwards, Domestic | $1.95亿2025-12-31 | $1.58亿 | +23.4% | $1.95亿 | $1.58亿 | +23.4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $1.56亿2025-12-31 | – | – | $1.56亿 | – | – |
| Deferred Tax Assets, Operating Loss Carryforwards, State and Local | $1.11亿2025-12-31 | $1.1亿 | +0.9% | $1.11亿 | $1.1亿 | +0.9% |
| Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration | $1770万2025-12-31 | $1780万 | -0.6% | $1770万 | $1780万 | -0.6% |
| Deferred Tax Assets, Other | $02025-12-31 | $9.1万 | -100.0% | $0 | $9.1万 | -100.0% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $5830万2025-12-31 | $2720万 | +114.2% | $5830万 | $2720万 | +114.2% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $424万2025-12-31 | $280万 | +51.5% | $424万 | $280万 | +51.5% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $17.4万2025-12-31 | $40.3万 | -56.8% | $17.4万 | $40.3万 | -56.8% |
| Deferred Tax Assets, Valuation Allowance | $2.65亿2025-12-31 | $1.64亿 | +61.4% | $2.65亿 | $1.64亿 | +61.4% |
| Deferred Tax Liabilities, Net | $24.7万2025-12-31 | $28.1万 | -12.1% | $24.7万 | $28.1万 | -12.1% |
| Deferred Tax Liabilities, Other | $22.3万2025-12-31 | $0 | – | $22.3万 | $0 | – |
| Deposits Assets, Noncurrent | $11.3万 | $4.6万 | +145.7% | $4.6万 | $4.6万 | 0.0% |
| Earnings Per Share, Basic | -$1.55 | -$0.81 | -91.4% | -$3.19 | -$1.01 | -215.8% |
| Earnings Per Share, Diluted | -$1.55 | -$0.81 | -91.4% | -$3.19 | -$1.01 | -215.8% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | -$2.6万 | -$6000 | -333.3% | -$8000 | -$14.8万 | +94.6% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$7550万 | – | – |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21.0% | 21.0% | 0.0% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-02